Open-to-Accrual Therapeutic Trials


Gynecologic Oncology

Trials are listed from Phase 1 to Phase 3, alphabetically.  Please click on the name of the Lead Clinical Research Coordinator (CRC) to request more information about each trial.

Protocol ID

Official Title

PI Name

Lead CRC

Disease Site

Phase

TESARO 4010-01-001      ClinicalTrials.gov   NCT0275284 Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors S. Ghamande Kelly Jenkins Advanced solid tumors I
ADXS001-004   ClinicalTrials.gov NCT02291055 Phase 1-2 Study of MEDI4736 Alone or In Combination With ADXS11-001 In Recurrent/Persistent or Metastatic Cervical or HPV+ Metastatic Head & Neck Cancer S. Ghamande Renee Townsend  Cervical I/II
NRG-GY007 ClinicalTrials.gov  NCT02713386 A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Protocol Type: Treatment S. Ghamande Melissa James Ovarian, Fallopian Tube, or Peritoneal Cancer I/II
CL-PTL-126     ClinicalTrials.gov   NCT03073525 A Randomized, Intra-patient Crossover, Safety, Biomarker and Anti-Tumor Activity Assessment of the Combination of Atezolizumab and Vigil in Patients with Advanced Gynecological Cancers S. Ghamande  Melissa James Cervical, Ovarian, and Uterine Cancer  II
Inovio HPV-201 ClinicalTrials.gov  NCT03180684 A Phase 2, Randomized, Open Label, Efficacy Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation With CELLECTRA® 2000 Alone or in Combination With Imiquimod, for the Treatment of HPV-16 and/or HPV-18 Related High Grade Squamous lntraepithelial Lesion (HSIL) of the Vulva Protocol D. Ferris Angela Goebel HPV Related HIgh Grade Squamous Intraepithelia Lesion (HSIL) II
LION C-145-04 ClinicalTrials.gov  NCT03108495 A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic or Persistent Cervical Carcinoma S. Ghamande Donna Wheatley Cervical Cancer II
Millennium C31004   ClinicalTrials.gov   NCT02725268 A Phase 2, Randomized Study of MLN0128 (a Dual TORC1/2 Inhibitor), MLN0128+MLN1117 (a PI3Kα Inhibitor), Weekly Paclitaxel, or the Combination of Weekly Paclitaxel and MLN0128 in Women With Advanced, Recurrent, or Persistent Endometrial Cancer S.  Ghamande Melissa James Endometrial Cancer II
MORAb-003-011 ClinicalTrials.gov  NCT02289950 A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination with Carboplatin plus Paclitaxel or Carboplatin plus Pegylated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian Cancer S. Ghamande Donna Wheatley Ovarian Cancer II
NRG-GY006  ClinicalTrials.gov NCT02466971 
A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer S. Ghamande  Kelly Adams Uterine Cervical or Vaginal Cancer II
CONCERTO  (D8488C00001)   ClinicalTrials.gov   NCT02889900 A Single Arm Phase IIb Study to Assess the Efficacy and Safety of the Combination of Cediranib and Olaparib in Women with Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer S. Ghamande  Melissa James  Ovarian, Fallopian Tube, or Primary Peritoneal Cancer  IIb
NRG-GY009 ClinicalTrials.gov NCT02839707 A Randomized, Phase II/III Study of Pegylated Lipsomal Doxorubicin and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer S. Ghamande Melissa James Ovarian Cancer II/III
CLOVIS/ CO-338-043   ClinicalTrials.gov NCT02855944 A Phase 3 Multicenter, Open-label, Randomized Study of Rucaparib versus Weekly Paclitaxel in Patients with BRCA-mutant or BRCA-like Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer S. Ghamande Donna Wheatley Ovarian, Fallopian Tube, or Primary Peritoneal Cancer III

GOG-0213 ClinicalTrials.gov NCT00565851

A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865, IND #113912) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865, IND #113912) Protocol S. Ghamande Inquiries Ovarian, Primary Peritoneal, and Fallopian Tube Cancer III
GOG-3005/ AbbVie  ClinicalTrials.gov   NCT02470585 A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer S. Ghamande Melissa James Ovarian, Fallopian Tube, or Primary Peritoneal Cancer III
GOG-3009/ ADXS001-02   ClinicalTrials.gov  NCT02853604 Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV S. Ghamande Kelly Adams Cervical Cancer III
GOG 3012/ PR-30-5017-C  ClinicalTrials.gov   NCT02655016
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy S. Ghamande Kelly Adams Ovarian Cancer III
MK3475-775  ClinicalTrials.gov  NCT03517449  A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Pembrolizumab Versy Treatment of Physician's Choice in Participants with Advanced Endometrial Cancer S. Ghamande Donna Wheatley Endometrial Cancer III
SOLO-3/ D0816C00010   ClinicalTrials.gov   NCT02282020 A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to Assess the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Single Agent Chemotherapy in the Treatment of Platinum Sensitive Relapsed Ovarian Cancer in Patients Carrying Germline BRCA1/2 Mutations S. Ghamande Melissa James Ovarian Cancer  III